Latest news with #RESEARCHTRIANGLEPARK
Yahoo
05-08-2025
- Business
- Yahoo
Leading by Example: JAGGAER 2024 ESG Impact Report Showcases Sustainability in Procurement
JAGGAER provides case study in cost cutting, risk management and sustainable growth RESEARCH TRIANGLE PARK, N.C., August 05, 2025--(BUSINESS WIRE)--JAGGAER, a global leader in enterprise procurement and supplier collaboration, has released its 2024 Environmental, Social and Governance (ESG) Impact Report, highlighting its progress in leading the procurement sector by example on sustainability. This year's report focuses on how the company embeds sustainability across its Source-to-Pay (S2P) solutions and internal operations to empower strategic cost reductions, 360° risk management and sustainable growth. As part of its efforts to anticipate customer needs, JAGGAER also undertook preparatory work for a Double Materiality Assessment, a key element in the EU's Corporate Sustainability Reporting Directive (CSRD), and a measure of accountability that signals a shift towards a more comprehensive understanding of both exposure to sustainability-related financial risks and broader impact on society and the environment. Andrew Roszko, CEO at JAGGAER, comments: "With a mission to guide the procurement and supply chain function into the future, at JAGGAER we practice what we preach. We experience first-hand the insights, transparency and strategic intelligence that our solutions provide businesses as they strive to manage risk, stay compliant and thrive. This report not only provides us with a critical benchmark for our environmental stewardship and role in the world but also reveals the breadth of intelligence available to support companies as they try to extract strategic data to cut costs, navigate volatile markets and stay competitive." In addition to this, the company received a Gold Medal from EcoVadis, placing it among the top 5% of all companies evaluated and within the top 1% among its industry peers. Environmental JAGGAER measured and published GHG emissions for the fourth consecutive year, achieving a 25% reduction in Scope 1 and Scope 2 emissions and a 43% reduction in Scope 3 emissions from the 2021 baseline. These results were supported by initiatives like AWS cloud migration and improved emissions data accuracy as well as environmentally responsible workplace practices. The latter were promoted through online collaboration tools, hybrid work, sustainable office rentals, paperless operations, and waste-reduction measures such as recycling and the promotion of reusable containers. In addition to this, through a partnership with Reforest'Action, the company contributed to reforestation projects in multiple countries, financing the planting of over 10,370 trees since 2019. These forests are expected to offset 1,556 tons of CO₂e over 30 years. Social As a signatory of the UN Global Compact, JAGGAER upholds its principles, ensuring non-discrimination and equal treatment based on merit and job requirements. In line with its commitment, the report reveals that in 2024 women made up 41.8% of JAGGAER's global workforce and held 36.1% of management positions. In support the happiness and health of employees, JAGGAER delivered wellbeing programs and mental health workshops across all regions, while maintaining a flexible work culture. To honor and cement company connections with local communities, employees dedicated over 380 volunteer hours to community service through local partnerships and initiatives. JAGGAER's efforts to create a serene and fair work environment were rewarded with two notable accolades: the Sunday Times – Best Places to Work 2024 (UK) and Gallagher's 2024 Best-In-Class Employer award (North America). Governance The ESG Steering Committee met quarterly to align on policy and homed in on data privacy and information security as core priorities, achieving industry-first AI management and security certifications, assurance measures, and full compliance with mandatory training. Employee engagement was high, with 100% of employees completing compliance training. Increased viability via the EcoVadis CAM solution, confirmed efforts to date and revealed that 71% of assessed high-spend or critical suppliers pose low GHG emissions risk. About JAGGAER: Procurement's intelligent source-to-pay and supplier collaboration platform. JAGGAER is a global leader in enterprise procurement and supplier collaboration, and the catalyst for enhancing human decision-making to accelerate business outcomes. We help organizations to manage and automate complex processes while enabling their highly resilient, accountable, and integrated supplier base. Backed by 30 years of expertise, our proven AI-powered industry-specific solutions, services, and partnerships form JAGGAER One, serving direct and indirect, upstream, and downstream, in settings demanding an intelligent and comprehensive source-to-pay solution. Our 1,200 global employees are obsessed with helping customers create value, transform their businesses, and accelerate their journey to Autonomous Commerce. View source version on Contacts Media contact For JAGGAER: Josephine OrnagoEmail: pr@ Cell: +39 3662250305 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
31-07-2025
- Business
- Globe and Mail
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025. The board has appointed Charlie Gayer, currently the company's chief commercial officer (CCO), as the company's next president, effective August 1, 2025, and next chief executive officer, effective January 1, 2026. Mr. Stonehouse will continue to serve on the board of directors and Mr. Gayer will join the company's board, effective January 1, 2026. Mr. Gayer has built and led the commercial organization responsible for the successful launch of ORLADEYO ® (berotralstat), bringing the first oral prophylactic therapy to people with hereditary angioedema and driving exceptional revenue growth, with expected peak sales of $1 billion. He also has played a pivotal role in shaping the company's recent business development strategy, including the planned sale of its European operations. 'We want to thank Jon for building BioCryst into the commercial, profitable company it is today, with such a bright future,' said Nancy Hutson, chair of the board. 'As part of our succession planning process, we have evaluated outstanding internal and external potential successors and Charlie stood out in that process, with an ability to build on the success he has achieved with ORLADEYO to further deliver on our mission to bring life-changing therapies to patients and create long-term value for our stakeholders.' 'I am delighted to hand the leadership responsibility of the company to Charlie. He has a proven track record of delivering results and is largely responsible for one of the best commercial launches of a rare disease drug in recent history. Charlie is a purpose-driven leader who understands our company's mission to serve patients living with rare diseases in extraordinary ways,' said Stonehouse. 'I am thrilled the board chose Charlie, as he understands we have worked hard to build a special culture at BioCryst that we believe has a direct impact on the company's performance in creating value. He is the perfect leader to take the company even further.' 'I am grateful for Jon's leadership and the patients-first culture he has fostered over my 10 years at BioCryst. Under his guidance, BioCryst has matured to the point where it is generating significantly increasing cash resources through ORLADEYO revenue while also advancing a promising pipeline. This is an exciting time for the company and I am deeply honored that the board has entrusted me to lead BioCryst into its next chapter," said Gayer. Mr. Gayer was promoted to CCO in January 2020, after joining the company in 2015 as vice president of global strategic marketing. Prior to BioCryst, he held U.S. and global commercial leadership roles in competitive rare disease categories at Talecris Biotherapeutics, Inc. and led U.S. alpha-1 antitrypsin deficiency marketing, and later European sales and marketing. After Grifols, S.A. acquired Talecris in 2011, he led the U.S. marketing team for the combined immune globulin portfolio of the two companies. Prior to joining Talecris, Mr. Gayer spent six years at GlaxoSmithKline in a range of professional marketing, consumer marketing and sales roles. He began his career as a strategic consultant for biopharmaceutical companies and spent three years as a business analyst at Genzyme Corporation. Mr. Gayer received his B.A. in politics from Princeton University and his M.B.A from the Fuqua School of Business of Duke University. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding future results, performance, achievements, plans and expectations regarding BioCryst's growth, pipeline, and value creation, BioCryst's expectations with respect to the transition of the CEO role, and statements related to the anticipated sale of BioCryst's European ORLADEYO business. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst's ability to successfully progress its pipeline development plans; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst's ability to successfully commercialize its products and product candidates; BioCryst's ability to successfully manage its growth and compete effectively; timing for achieving and sustainability of profitability and positive cash flow may not meet management's expectations; statements regarding financial goals and the attainment of such goals may differ from actual results based on market factors and BioCryst's ability to execute its operational, capital deployment and budget plans; actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges; and BioCryst's completion of the planned sale of its European operations on anticipated terms and timing, including obtaining required regulatory approvals. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst's projections and forward-looking statements.
Yahoo
31-07-2025
- Business
- Yahoo
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025. The board has appointed Charlie Gayer, currently the company's chief commercial officer (CCO), as the company's next president, effective August 1, 2025, and next chief executive officer, effective January 1, 2026. Mr. Stonehouse will continue to serve on the board of directors and Mr. Gayer will join the company's board, effective January 1, 2026. Mr. Gayer has built and led the commercial organization responsible for the successful launch of ORLADEYO® (berotralstat), bringing the first oral prophylactic therapy to people with hereditary angioedema and driving exceptional revenue growth, with expected peak sales of $1 billion. He also has played a pivotal role in shaping the company's recent business development strategy, including the planned sale of its European operations. 'We want to thank Jon for building BioCryst into the commercial, profitable company it is today, with such a bright future,' said Nancy Hutson, chair of the board. 'As part of our succession planning process, we have evaluated outstanding internal and external potential successors and Charlie stood out in that process, with an ability to build on the success he has achieved with ORLADEYO to further deliver on our mission to bring life-changing therapies to patients and create long-term value for our stakeholders.' 'I am delighted to hand the leadership responsibility of the company to Charlie. He has a proven track record of delivering results and is largely responsible for one of the best commercial launches of a rare disease drug in recent history. Charlie is a purpose-driven leader who understands our company's mission to serve patients living with rare diseases in extraordinary ways,' said Stonehouse. 'I am thrilled the board chose Charlie, as he understands we have worked hard to build a special culture at BioCryst that we believe has a direct impact on the company's performance in creating value. He is the perfect leader to take the company even further.' 'I am grateful for Jon's leadership and the patients-first culture he has fostered over my 10 years at BioCryst. Under his guidance, BioCryst has matured to the point where it is generating significantly increasing cash resources through ORLADEYO revenue while also advancing a promising pipeline. This is an exciting time for the company and I am deeply honored that the board has entrusted me to lead BioCryst into its next chapter," said Gayer. Mr. Gayer was promoted to CCO in January 2020, after joining the company in 2015 as vice president of global strategic marketing. Prior to BioCryst, he held U.S. and global commercial leadership roles in competitive rare disease categories at Talecris Biotherapeutics, Inc. and led U.S. alpha-1 antitrypsin deficiency marketing, and later European sales and marketing. After Grifols, S.A. acquired Talecris in 2011, he led the U.S. marketing team for the combined immune globulin portfolio of the two companies. Prior to joining Talecris, Mr. Gayer spent six years at GlaxoSmithKline in a range of professional marketing, consumer marketing and sales roles. He began his career as a strategic consultant for biopharmaceutical companies and spent three years as a business analyst at Genzyme Corporation. Mr. Gayer received his B.A. in politics from Princeton University and his M.B.A from the Fuqua School of Business of Duke University. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding future results, performance, achievements, plans and expectations regarding BioCryst's growth, pipeline, and value creation, BioCryst's expectations with respect to the transition of the CEO role, and statements related to the anticipated sale of BioCryst's European ORLADEYO business. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst's ability to successfully progress its pipeline development plans; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst's ability to successfully commercialize its products and product candidates; BioCryst's ability to successfully manage its growth and compete effectively; timing for achieving and sustainability of profitability and positive cash flow may not meet management's expectations; statements regarding financial goals and the attainment of such goals may differ from actual results based on market factors and BioCryst's ability to execute its operational, capital deployment and budget plans; actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges; and BioCryst's completion of the planned sale of its European operations on anticipated terms and timing, including obtaining required regulatory approvals. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst's projections and forward-looking statements. BCRXW Contact:Investors:investorrelations@ Media:media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-07-2025
- Business
- Yahoo
Merakris Therapeutics Selected as Finalist for 2025 Advanced Would Care Summit Innovation Showcase
MTX-001, an investigational new drug, aims to become the first subcutaneous biologic drug therapy for chronic non-healing venous leg ulcers RESEARCH TRIANGLE PARK, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces its amniotic fluid-derived regenerative biologic, MTX-001, an investigational new drug, is a finalist for the Innovation Showcase: Early-Stage Disruptors in Wound Care at the 2025 Advanced Wound Care (AWC) Summit in Boston. Only six companies were chosen by the AWC selection committee to present at the event on July 17, 2025 at 8:30am ET. At the Innovation Showcase, Chris Broderick, Merakris Therapeutics CEO, will present an overview of MTX-001, including promising key findings from the ongoing Phase 2 clinical trial evaluating the therapy in patients with non-healing venous leg ulcers (VLUs) also referred to as venous stasis ulcers (VSUs). 'Non-healing VLUs affect millions of people and a substantial number of patients fail to heal with today's standard therapies,' said Broderick. 'MTX-001 represents a new class of regenerative biologics delivered via subcutaneous injection. This innovation is proving to promote healing in chronic venous wounds and improve patient outcomes.' Also at the 2025 Advanced Wound Care Summit, Sean O'Connell, PhD, Head of Medical Affairs at Merakris Therapeutics, will present 'Injectable Drugs as the Next Big Step for Advanced Wound Care' on July 16th at 3:15pm. His talk will review the MTX-001 clinical program, interim Phase 2 results, and outline upcoming plans for a Phase 3 clinical trial. He will also highlight the unmet needs in the chronic wound market and the emerging role of injectable biologics in outpatient care. For strategic partnership and collaboration opportunities, please visit For more information about the MTX-001 clinical trial or Merakris' Expanded Access Program, please contact medaffairs@ About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA. CONTACT: PR Contact: Garth Miller Nova Marketing Solutions 919-923-3505Sign in to access your portfolio
